A Study To Assess The Duration Of Action Of PF-03526299 In Asthmatic Subjects Following Allergen Challenge

Back to Search
Print
Bookmark Trial

NCT01299467

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Asthma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-60 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male and/or female subjects between the ages of 18 and 60 years, inclusive.

- A history or diagnosis of asthma that requires the use of beta 2 agonist bronchodilators (eg Salbutamol).

- Women who could become pregnant must use appropriate birth control throughout the study and pregnancy tests must be negative on entering the study and prior to dosing in the clinic.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects who have been hospitalized for the treatment of asthma within three months
prior to study entry, or have been hospitalized more than twice in last 12 months.


- Subjects who have experienced a lower respiratory tract infection (eg bronchitis or
pneumonia) or significant asthma instability in the 4 weeks prior to study entry.


- Severe additional disease other than asthma

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

AsthmaPF-04191834 Single Dose Bronchodilatory Study In Asthma.
NCT00723021
  1. Baltimore, Maryland
  2. North Dartmouth, Massachusetts
  3. Kalamazoo, Michigan
  4. Omaha, Nebraska
ALL GENDERS
18 Years+
years
MULTIPLE SITES
AsthmaA Study To Estimate The Relative Bioavailability Of PF-00258210 Administered Alone Or In Combination With PF-00610355
NCT01043276
  1. Singapore,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
AsthmaStudy Evaluating Etanercept in Moderate to Severe Asthma
NCT00141791
  1. Birmingham, Alabama
  2. Denver, Colorado
  3. Sarasota, Florida
  4. Tallahassee, Florida
  5. Valrico, Florida
  6. Covington, Louisiana
  7. Wheaton, Maryland
  8. Boston, Massachusetts
  9. Rockville Center, New York
  10. Winston-Salem, North Carolina
  11. Portland, Oregon
  12. Richmond, Virginia
  13. Madison, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
AsthmaA Study of the Safety and Efficacy of Tofimilast in Adult Asthmatics
NCT00150397
  1. Encinitas, California
  2. Riverside, California
  3. DeLand, Florida
  4. Atlanta, Georgia
  5. Normal, Illinois
  6. Madisonville, Kentucky
  7. North Dartmouth, Massachusetts
  8. Springfield, Massachusetts
  9. Minneapolis, Minnesota
  10. Skillman, New Jersey
  11. Cincinnati, Ohio
  12. Lincoln, Rhode Island
  13. Kingsport, Tennessee
  14. Nashville, Tennessee
  15. Dallas, Texas
  16. Madison, Wisconsin
  17. Barrio Aranjuez, San Jose
  18. San Jose,
  19. Mumbai, Maharashtra
  20. Chennai, Tamil Nadu
  21. Vellore, Tamilnadu
  22. Noida, Uttar Pradesh
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study To Assess The Duration Of Action Of PF-03526299 In Asthmatic Subjects Following Allergen Challenge
Official Title  ICMJE A Randomized, Double-Blind, Third Party Open, Double-Dummy, Placebo-Controlled, 3-Way Crossover Study To Determine The Duration Of Action Of Inhaled Doses Of PF-03526299 On Allergen-Induced Airway Responses In Mild Asthmatic Subjects
Brief Summary The purpose of this study is to find out how long the effect of PF-03526299 last after it is inhaled by assessing the lung function of mild asthma patients after they have been exposed to allergen
Detailed Description To assess duration of action of the compound in suppressing the early and late allergen response in asthma patients
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Condition  ICMJE Asthma
Intervention  ICMJE
  • Drug: Active (PF-03526299)
    Capsules for inhalation, 1.396 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
  • Drug: Active (PF-03526299)
    Capsules for inhalation, 1.396 mg twice a day for up to 12 days. Last dose given 8 hrs before allergen challenge
  • Drug: Placebo
    Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
  • Drug: Active (PF-03526299)
    Capsules for inhalation, 4.188 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
  • Drug: Active (PF-03526299)
    Capsules for inhalation, 4.188 mg twice a day for up to 12 days. Last dose given 8hrs before allergen challenge
Study Arms  ICMJE
  • Experimental: Dose 1 (0.5 hours)
    Intervention: Drug: Active (PF-03526299)
  • Experimental: Dose 1 (8 hours)
    Intervention: Drug: Active (PF-03526299)
  • Placebo Comparator: Dose 1 (placebo)
    Intervention: Drug: Placebo
  • Experimental: Dose 2 (0.5 hr)
    Intervention: Drug: Active (PF-03526299)
  • Experimental: Dose 2 (8 hours)
    Intervention: Drug: Active (PF-03526299)
  • Placebo Comparator: Dose 2 (placebo)
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: November 30, 2011)		0
Original Estimated Enrollment  ICMJE
 (submitted: February 16, 2011)		24
Estimated Study Completion Date  ICMJE February 2012
Estimated Primary Completion Date February 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male and/or female subjects between the ages of 18 and 60 years, inclusive.
  • A history or diagnosis of asthma that requires the use of beta 2 agonist bronchodilators (eg Salbutamol).
  • Women who could become pregnant must use appropriate birth control throughout the study and pregnancy tests must be negative on entering the study and prior to dosing in the clinic.

Exclusion Criteria:

  • Subjects who have been hospitalized for the treatment of asthma within three months prior to study entry, or have been hospitalized more than twice in last 12 months.
  • Subjects who have experienced a lower respiratory tract infection (eg bronchitis or pneumonia) or significant asthma instability in the 4 weeks prior to study entry.
  • Severe additional disease other than asthma
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 60 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01299467
Other Study ID Numbers  ICMJE A9291006
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP